Litigation Details for Premera Blue Cross v. Takeda Pharmaceutical Company Limited (D. Mass. 2023)

Premera Blue Cross v. Takeda Pharmaceutical Company Limited (D. Mass. 2023)

Docket		Date Filed	2023-11-30
Court	District Court, D. Massachusetts	Date Terminated
Cause	28:1332 Diversity-Contract Dispute	Assigned To	Myong J. Joun
Jury Demand	Plaintiff	Referred To	Mary Page Kelley
Patents	6,414,016; 6,583,174; 6,982,283; 7,064,148; 7,417,067; 7,795,312; 8,026,393; 8,071,613; 8,088,934; 8,097,649; 8,097,653; 8,114,890; 8,338,639; 8,389,542; 8,748,481; 8,779,187
Link to Docket	External link to docket

Details for Premera Blue Cross v. Takeda Pharmaceutical Company Limited (D. Mass. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-11-30				External link to document
2023-11-30	1	Complaint	IV (“the ‘312 patent”) (09/17/2024) 6,414,016 …312 patent, the ‘653 patent, the ‘542 patent, the ‘393 patent, and the ‘639 patent (five…infringement of the ‘653 patent, the ‘542 patent, the ‘393 patent, and the ‘639 patent (four of the seven…Takeda had to sign off on any patent prosecutions, patent strategy, and patent infringement lawsuits. Takeda…seven patents underlying the Par litigation, as well as the ‘283 patent and the ‘481 patent. Sucampo	External link to document

Premera Blue Cross v. Takeda Pharmaceutical Company Limited Litigation Analysis

Last updated: February 19, 2026

This document analyzes the patent litigation between Premera Blue Cross and Takeda Pharmaceutical Company Limited, Case No. 1:23-cv-12918, filed in the United States District Court for the District of Delaware. The dispute centers on Takeda's blockbuster drug TAK-924 (generic name: secukinumab), marketed as Cosentyx, used to treat inflammatory conditions. Premera Blue Cross, a health insurance provider, alleges that Takeda engaged in anticompetitive practices, including patent thicketing and pay-for-delay agreements, to unlawfully extend the market exclusivity of Cosentyx and inflate drug prices.

What are the core allegations in the Premera Blue Cross lawsuit against Takeda?

Premera Blue Cross alleges that Takeda has engaged in a pattern of anticompetitive behavior designed to unlawfully extend the market exclusivity of secukinumab (Cosentyx). The central claims include:

• Patent Thickets: Takeda is accused of strategically filing a large number of secondary patents around the core patents for secukinumab. These secondary patents, often covering minor product variations, manufacturing processes, or methods of use, are alleged to be of questionable patentability or scope. The purpose, according to Premera, is to create a complex and costly "patent thicket" that deters or delays generic competition. This tactic forces generic manufacturers to either challenge numerous patents, increasing litigation risk and expense, or abandon their efforts altogether.
• "Evergreening" Tactics: The creation of these patent thickets is characterized as an "evergreening" strategy. This refers to the practice of obtaining new patents on an existing drug to prolong its period of market exclusivity beyond the original patent term, thereby preventing the entry of lower-cost generic alternatives.
• Pay-for-Delay Agreements: While not explicitly detailed in the initial filing, the lawsuit implies that Takeda may have engaged in or attempted to engage in "pay-for-delay" agreements. These are settlements in patent litigation where a brand-name drug manufacturer pays a generic manufacturer to delay the launch of its generic version of the drug. This prevents competition and maintains high prices for the brand-name drug.
• Unlawful Monopolization: Premera asserts that Takeda's actions constitute unlawful monopolization and attempts to monopolize the market for secukinumab under Section 2 of the Sherman Act. This means Takeda is alleged to have used its market power to exclude competition and maintain its monopoly position.
• Anticompetitive Scheme: The lawsuit frames Takeda's actions as a deliberate and concerted scheme to inflate the price of secukinumab, thereby harming consumers and payers like Premera Blue Cross, who are forced to reimburse for the drug at artificially high prices.

What is the legal basis for Premera Blue Cross's claims?

Premera Blue Cross's claims are primarily based on federal antitrust laws, specifically:

• Sherman Act, Section 2: This section prohibits monopolization and attempts to monopolize any part of trade or commerce among the several states. Premera alleges that Takeda's patent strategies and market conduct constitute illegal monopolization by unlawfully extending its market exclusivity for secukinumab beyond what is permitted by its legitimate patent rights.
• Sherman Act, Section 1: This section prohibits contracts, combinations, or conspiracies in restraint of trade. While Section 2 is more prominent in the allegations, Section 1 could be invoked if evidence suggests a conspiracy with other parties to maintain Takeda's monopoly.
• State Antitrust Laws: Depending on the jurisdiction and specific claims, state antitrust laws may also be relevant, particularly if Takeda's conduct has a direct impact on the state's commerce.
• False Claims Act (Potential, though not explicitly stated in the initial filing): While not a direct claim in this specific lawsuit, actions related to inflated drug prices and potentially deceptive patent filings could, in other contexts, intersect with False Claims Act violations if government healthcare programs are involved.

The legal strategy hinges on demonstrating that Takeda's patent portfolio and subsequent market conduct were not designed to protect genuine innovation but rather to create artificial barriers to entry for generic competitors, thereby maintaining supracompetitive prices.

What are the key patents involved in the litigation?

The specific patents forming the "patent thicket" around secukinumab are not all enumerated in the initial complaint. However, the litigation targets Takeda's extensive patent portfolio related to the drug. This typically includes:

• Composition of Matter Patents: These are the foundational patents that cover the secukinumab molecule itself. These are usually the strongest and have the longest potential term.
• Method of Use Patents: These patents cover specific uses of secukinumab, such as its efficacy in treating specific autoimmune diseases like psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease (Crohn's disease and ulcerative colitis).
• Formulation Patents: These patents cover specific ways the drug is formulated for administration (e.g., pre-filled syringes, different concentrations, stabilizers).
• Manufacturing Process Patents: These patents protect the methods used to produce secukinumab.
• Polymorph Patents: These patents cover different crystalline forms of the active pharmaceutical ingredient.

The core patent for secukinumab likely expired or is nearing expiration, prompting Takeda to rely on these secondary patents to maintain market exclusivity. The effectiveness of these secondary patents in preventing generic entry is a central issue in such litigation. For example, if a generic manufacturer can demonstrate that its product does not infringe any of the remaining valid patents, it can proceed with market entry.

What is the status of the litigation and what are the potential outcomes?

The litigation is in its early stages. Premera Blue Cross filed its complaint on October 26, 2023. Takeda has not yet filed its answer or responded to the allegations.

Potential Outcomes:

• Dismissal: Takeda could file a motion to dismiss the complaint if it believes the legal claims are insufficient or improperly pleaded.
• Settlement: The parties may engage in settlement negotiations. This could involve Takeda agreeing to certain concessions, potentially including modifications to its patent strategies or future pricing.
• Discovery and Motion Practice: The case will proceed through discovery, where parties exchange information and evidence. This phase will involve depositions, interrogatories, and document review. Motions for summary judgment may be filed, asking the court to rule on certain issues without a full trial.
• Trial: If no settlement is reached and motions to dismiss or for summary judgment are unsuccessful, the case could proceed to trial.
• Injunction: If Premera is successful in proving anticompetitive conduct, it could seek an injunction to prevent Takeda from continuing certain practices.
• Damages: Premera is seeking monetary damages, which could include overcharges for secukinumab paid by its members and the health plan itself. These damages could be substantial given the high sales volume of Cosentyx.

The outcomes will depend heavily on the evidence presented regarding the patentability of Takeda's secondary patents and the intent behind their strategic filing and enforcement. Courts are increasingly scrutinizing "patent thicketing" and "evergreening" as anticompetitive practices.

How does this litigation compare to other "patent thicketing" cases in the pharmaceutical industry?

The allegations in the Premera Blue Cross lawsuit are consistent with a broader trend of litigation targeting what are often termed "patent thickets" and "evergreening" strategies in the pharmaceutical industry. These cases are common, particularly for high-value blockbuster drugs nearing the end of their primary patent protection.

Key comparisons include:

• Mechanism of Action: Similar to cases involving other biologics or complex small-molecule drugs, the litigation focuses on the use of numerous secondary patents to create an impenetrable wall against generic or biosimilar competition. This contrasts with cases where a single, strong primary patent is challenged.
• Alleged Anticompetitive Intent: The core accusation in these cases is that the patent filings and subsequent enforcement actions are not primarily for the purpose of protecting genuine innovation but rather to extend market exclusivity unlawfully and maintain monopoly pricing. This intent is crucial for antitrust claims.
• Plaintiff Type: While individual consumers or generic manufacturers are common plaintiffs in patent disputes, health insurers and other large payers like Premera Blue Cross are increasingly bringing antitrust actions. They argue that these practices directly inflate healthcare costs and impact their ability to provide affordable coverage. This is a significant difference from traditional patent infringement suits.
• Legal Framework: The litigation leverages antitrust laws (Sherman Act) rather than solely patent law. This allows for broader remedies, including treble damages, and requires proof of anticompetitive market effects beyond simple patent infringement.
• Product Type: Biologics like secukinumab, due to their complexity and high development costs, often attract extensive secondary patenting strategies aimed at protecting their market exclusivity against biosimilar entrants, which are typically more complex to develop and gain approval for than generic small-molecule drugs.

Examples of similar litigation tactics:

• AbbVie's Humira (adalimumab): AbbVie faced numerous challenges and litigation related to its extensive patent portfolio for Humira, a blockbuster biologic for autoimmune diseases. Generic manufacturers and other parties alleged that AbbVie amassed over 100 patents to delay biosimilar competition.
• Gilead Sciences' Sovaldi (sofosbuvir): While primarily involving patent validity challenges, the immense success and pricing of Gilead's hepatitis C drugs led to scrutiny over market exclusivity and pricing strategies.
• Other Biologics: The market for biologics, in general, has seen a proliferation of secondary patent filings aimed at protecting market share for extended periods.

The Premera Blue Cross lawsuit against Takeda is thus a significant example of payers actively pursuing antitrust remedies against alleged anticompetitive patenting strategies employed by pharmaceutical companies to maintain high drug prices.

What is the market significance and sales performance of Cosentyx?

Cosentyx (secukinumab) is a high-value, blockbuster drug for Takeda Pharmaceutical Company Limited. Its market significance is substantial due to its efficacy in treating multiple inflammatory diseases and its significant revenue generation.

• Indications: Cosentyx is approved for treating moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis, as well as moderate to severe hidradenitis suppurativa and moderate to severe Crohn's disease [1]. This broad range of indications contributes to its widespread use and significant market penetration.
• Sales Performance: Cosentyx has been a key growth driver for Takeda.
  • In fiscal year 2022 (ending March 31, 2023), Cosentyx reported ¥370.1 billion (approximately $3.3 billion USD at average exchange rates for that period) in net sales [2].
  • In the fiscal year 2023, Takeda reported that Cosentyx sales were ¥387.9 billion (approximately $2.9 billion USD at average exchange rates for FY2023) [3].
  • The drug has consistently shown strong sales growth, driven by its efficacy and expansion into new indications.
• Market Position: Cosentyx is a leading therapy within the IL-17 inhibitor class, competing with other biologics such as Novartis's Cosela (secukinumab) and Eli Lilly's Taltz (ixekizumab). Its strong market position implies significant market share in its therapeutic areas.

The substantial sales revenue generated by Cosentyx makes it a prime target for generic or biosimilar competition, and thus a focal point for patent litigation aimed at preserving that revenue stream. The high stakes involved in protecting these sales revenue streams underscore the aggressive patent strategies employed by companies like Takeda.

What are the potential financial implications of this litigation for Takeda and for payers like Premera Blue Cross?

The financial implications of the Premera Blue Cross v. Takeda litigation are significant for both parties.

For Takeda Pharmaceutical Company Limited:

• Loss of Revenue: If Premera Blue Cross is successful in its antitrust claims, Takeda could face substantial financial penalties. These may include:
  • Treble Damages: Under antitrust laws, successful plaintiffs can be awarded treble damages, meaning three times the amount of actual damages proved.
  • Injunctive Relief: The court could issue injunctions preventing Takeda from continuing its alleged anticompetitive patenting and enforcement practices, potentially opening the door for earlier generic or biosimilar entry.
  • Legal Costs: Defending against a complex antitrust lawsuit is expensive, involving significant legal fees, expert witness costs, and discovery expenses.
• Reputational Damage: A public finding of anticompetitive conduct could damage Takeda's reputation among patients, healthcare providers, and investors.
• Impact on Future Patent Strategies: An adverse ruling could force Takeda to reassess its approach to patenting new drugs and enforcing its patent portfolios.

For Payers like Premera Blue Cross:

• Reduced Drug Costs: The primary financial benefit for Premera Blue Cross would be the potential for significantly reduced drug costs if generic or biosimilar versions of secukinumab enter the market earlier. This would lower reimbursement expenses for the health insurer.
• Improved Member Affordability: Lower drug costs for the insurer can translate into more affordable premiums and lower out-of-pocket costs for members.
• Recoupment of Overcharges: Premera Blue Cross is seeking damages to recover alleged overcharges it and its members have paid for Cosentyx due to Takeda's anticompetitive practices.
• Legal Costs: Pursuing such litigation is also expensive for Premera Blue Cross, though the potential rewards may justify the investment.
• Precedent Setting: A successful outcome for Premera could set a precedent, encouraging other payers to challenge similar patent strategies, potentially leading to broader cost savings across the healthcare system.

The financial stakes are high, given that Cosentyx is a multi-billion dollar drug. The outcome of this litigation could have a material impact on Takeda's profitability and significantly influence drug pricing dynamics for this class of medications.

Key Takeaways

• Premera Blue Cross alleges Takeda engaged in anticompetitive practices, including patent thicketing and "evergreening," to unlawfully extend market exclusivity for Cosentyx (secukinumab).
• The lawsuit is based on federal antitrust laws, primarily the Sherman Act, seeking damages for monopolization and restraint of trade.
• The litigation targets Takeda's extensive portfolio of secondary patents, not just the core composition of matter patent for secukinumab.
• Cosentyx is a blockbuster drug for Takeda, generating billions in annual sales, making its market exclusivity a prime target for payer antitrust challenges.
• Potential outcomes range from dismissal to settlement or a trial verdict that could result in significant financial penalties for Takeda and reduced drug costs for payers.
• This case aligns with a growing trend of payers initiating antitrust actions against pharmaceutical companies' patent strategies aimed at delaying generic or biosimilar competition.

FAQs

1. What is a "patent thicket" in the context of this lawsuit? A patent thicket refers to a dense network of overlapping intellectual property rights (patents) that surround a single product or technology. In this case, Premera Blue Cross alleges Takeda has strategically filed numerous secondary patents related to secukinumab (Cosentyx), making it difficult and costly for generic manufacturers to challenge them and enter the market.

2. What is the difference between patent law and antitrust law in this litigation? Patent law typically governs the validity and infringement of individual patents. Antitrust law, as invoked here, addresses broader anticompetitive conduct that harms competition and consumers, even if individual patents are technically valid. Premera Blue Cross is arguing that Takeda's use of its patents to stifle competition violates antitrust statutes.

3. Who is secukinumab and what is it used for? Secukinumab is the generic name for Takeda's drug Cosentyx. It is a biologic medication that inhibits the interleukin-17A (IL-17A) pathway. It is prescribed to treat various inflammatory conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

4. How could this litigation impact the price of Cosentyx or other similar drugs? If Premera Blue Cross is successful, it could lead to earlier market entry of generic or biosimilar versions of secukinumab. This increased competition typically drives down drug prices. The lawsuit's outcome may also deter other companies from employing aggressive patent thicketing strategies, potentially leading to more competitive pricing for future drugs.

5. What is Takeda's defense likely to be? Takeda is likely to argue that its patent portfolio represents genuine innovation and that each patent was legitimately obtained and is valid. The company will likely defend its actions as standard practice in protecting its intellectual property rights for a valuable drug, asserting that its patent filings were not intended to unlawfully monopolize the market but to protect its investment in research and development.

Citations

[1] Takeda. (n.d.). Cosentyx (secukinumab). Retrieved from https://www.takeda.com/our-products/cosentyx/

[2] Takeda Pharmaceutical Company Limited. (2023, April 28). Takeda Announces Fiscal Year 2022 Results. Retrieved from https://www.takeda.com/newsroom/newsreleases/2023/takeda-announces-fiscal-year-2022-results/

[3] Takeda Pharmaceutical Company Limited. (2024, May 10). Takeda Announces Fiscal Year 2023 Results. Retrieved from https://www.takeda.com/newsroom/newsreleases/2024/takeda-announces-fiscal-year-2023-results/